Taysha Gene Therapies (NASDAQ:TSHA) Earns “Buy” Rating from Chardan Capital
Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report)‘s stock had its “buy” rating restated by stock analysts at Chardan Capital in a research report issued on Wednesday,Benzinga reports. They currently have a $7.00 price objective on the stock. Chardan Capital’s price target suggests a potential upside of 340.25% from the company’s previous close. Other research […]
Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report)‘s stock had its “buy” rating restated by stock analysts at Chardan Capital in a research report issued on Wednesday,Benzinga reports. They currently have a $7.00 price objective on the stock. Chardan Capital’s price target suggests a potential upside of 340.25% from the company’s previous close. Other research […]
